Povidone-Iodine for Nasal Decolonization

• Status: Not yet recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy and tolerability of 10% povidone-iodine in eliminating nasal carriage of Staphylococcus aureus and MRSA. To determine whether a more convenient, single-dose, pre-operative 10% povidone-iodine (PI) application is effective in reducing nasal carriage of S. aureus and MRSA. We expect a statistically significant decrease in S. aureus/MRSA colonization in nasal cultures taken perioperatively after intervention in patients who received pretreatment with PI as compared to patients who received normal saline (NS).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rutgers, The State University of New Jersey
• Treatments: Povidone; Povidone-Iodine

Criteria

Inclusion Criteria:

• community-based patients ages 18-80, American Society of Anesthesiology (ASA) 1-3 who will be undergoing an outpatient surgery scheduled for at least 1 hour and up to 6 hours duration.

Exclusion Criteria:

• pregnancy, allergy to povidone-iodine, infectious indication for surgery or preexisting known infection/wound, known immunocompromised state, use of chemotherapy or steroids within 1 month prior to surgery, use of antimicrobial therapy within 30 days prior to surgery. Additionally, patients presenting for surgeries where field avoidance prevents intraoperative access to the nares will be excluded.